Article info

Download PDFPDF

BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance

Authors

  1. Correspondence to Dr Francesco Bertoni; frbertoni{at}mac.com
View Full Text

Citation

Tarantelli C, Bernasconi E, Gaudio E, et al
BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance

Publication history

  • Received April 25, 2018
  • Revised July 13, 2018
  • Accepted July 16, 2018
  • First published September 26, 2018.
Online issue publication 
September 26, 2018

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.